Key Points
- Liquidia insider Jason Adair sold 73,631 shares at an average price of $69.09, generating approximately $5.09 million. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced his stake by 29.66% to 174,606 shares.
- Liquidia shares opened at $70.49, with a $6.31 billion market capitalization and a 12-month trading range of $21.15 to $93.61. The stock’s 50-day moving average was $79.31, compared with $56.65 for its 200-day average.
- The company reported quarterly revenue of $171.68 million, up 1,842.1% year over year, but earnings per share of $0.74 fell slightly short of estimates. Analyst sentiment was mixed, with an overall consensus rating of “Hold” and an average price target of $98.08.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 73,631 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $69.09, for a total value of $5,087,165.79. Following the completion of the sale, the insider owned 174,606 shares in the company, valued at $12,063,528.54. This trade represents a 29.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jason Adair also recently made the following trade(s):
- On Monday, July 27th, Jason Adair sold 688 shares of Liquidia stock. The stock was sold at an average price of $87.53, for a total value of $60,220.64.
- On Monday, July 13th, Jason Adair sold 7,863 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total value of $562,283.13.
Liquidia Price Performance
Shares of NASDAQ LQDA opened at $70.49 on Wednesday. The firm has a market capitalization of $6.31 billion, a P/E ratio of 51.45 and a beta of 0.58. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The stock's 50-day simple moving average is $79.31 and its two-hundred day simple moving average is $56.65. Liquidia Corporation has a twelve month low of $21.15 and a twelve month high of $93.61.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business's revenue was up 1842.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.49) EPS. As a group, equities analysts anticipate that Liquidia Corporation will post 2.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the 4th quarter valued at $25,000. NewEdge Advisors LLC purchased a new stake in Liquidia during the 2nd quarter valued at $25,000. Covestor Ltd grew its holdings in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after acquiring an additional 359 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock worth $83,000 after acquiring an additional 4,927 shares during the last quarter. Finally, Globeflex Capital L P purchased a new position in shares of Liquidia in the second quarter valued at about $175,000. Institutional investors own 64.54% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a "buy" rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Bank of America boosted their price target on shares of Liquidia from $79.00 to $92.00 and gave the stock a "neutral" rating in a research note on Thursday, August 13th. Wells Fargo & Company upped their price target on shares of Liquidia from $62.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Liquidia in a research note on Friday, July 17th. Finally, BTIG Research lifted their price objective on Liquidia from $109.00 to $111.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $98.08.
Read Our Latest Stock Report on LQDA
Liquidia Company Profile
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
